DE60228972D1 - Glp 1 exendin 4 peptidanaloga und deren verwendungen - Google Patents

Glp 1 exendin 4 peptidanaloga und deren verwendungen

Info

Publication number
DE60228972D1
DE60228972D1 DE60228972T DE60228972T DE60228972D1 DE 60228972 D1 DE60228972 D1 DE 60228972D1 DE 60228972 T DE60228972 T DE 60228972T DE 60228972 T DE60228972 T DE 60228972T DE 60228972 D1 DE60228972 D1 DE 60228972D1
Authority
DE
Germany
Prior art keywords
exendin
glp
polypeptide
peptide analog
relates
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60228972T
Other languages
English (en)
Inventor
Nigel H Greig
Josephine Egan
Maire Doyle
Harold Holloway
Tracy Ann Perry
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
US Department of Health and Human Services
Original Assignee
US Department of Health and Human Services
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=23196575&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DE60228972(D1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by US Department of Health and Human Services filed Critical US Department of Health and Human Services
Application granted granted Critical
Publication of DE60228972D1 publication Critical patent/DE60228972D1/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/02—Antidotes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/12—Antidiuretics, e.g. drugs for diabetes insipidus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/57563—Vasoactive intestinal peptide [VIP]; Related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/2278—Vasoactive intestinal peptide [VIP]; Related peptides (e.g. Exendin)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/26—Glucagons
DE60228972T 2001-07-31 2002-07-30 Glp 1 exendin 4 peptidanaloga und deren verwendungen Expired - Lifetime DE60228972D1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US30907601P 2001-07-31 2001-07-31
PCT/US2002/024141 WO2003011892A2 (en) 2001-07-31 2002-07-30 Glp-1 exendin-4 peptide analogs and uses thereof

Publications (1)

Publication Number Publication Date
DE60228972D1 true DE60228972D1 (de) 2008-10-30

Family

ID=23196575

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60228972T Expired - Lifetime DE60228972D1 (de) 2001-07-31 2002-07-30 Glp 1 exendin 4 peptidanaloga und deren verwendungen

Country Status (8)

Country Link
US (4) US7576050B2 (de)
EP (3) EP2022505B1 (de)
JP (3) JP2005501058A (de)
AT (2) ATE536881T1 (de)
AU (2) AU2002317599B2 (de)
CA (1) CA2455963C (de)
DE (1) DE60228972D1 (de)
WO (1) WO2003011892A2 (de)

Families Citing this family (137)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050272652A1 (en) * 1999-03-29 2005-12-08 Gault Victor A Peptide analogues of GIP for treatment of diabetes, insulin resistance and obesity
ATE346093T1 (de) * 2000-06-16 2006-12-15 Lilly Co Eli Analoge des glucagon ähnlichen peptid-1
EP2022505B1 (de) 2001-07-31 2011-12-14 The Government of the United States of America, as represented by the Secretary of the Department of Health and Human Services GLP-1, Exendin-4, Peptid-Analoga und Verwendungen davon
ES2545090T3 (es) 2001-12-21 2015-09-08 Human Genome Sciences, Inc. Proteínas de fusión de albúmina y GCSF
CA2468700A1 (en) * 2002-01-08 2003-07-17 Eli Lilly And Company Extended glucagon-like peptide-1 analogs
GB0205693D0 (en) * 2002-03-09 2002-04-24 Astrazeneca Ab Chemical compounds
US7731947B2 (en) 2003-11-17 2010-06-08 Intarcia Therapeutics, Inc. Composition and dosage form comprising an interferon particle formulation and suspending vehicle
AU2004231461B2 (en) * 2003-03-19 2009-11-12 Eli Lilly And Company Polyethelene glycol linked GLP-1 compounds
CN102174102A (zh) * 2003-05-15 2011-09-07 塔夫茨大学信托人 肽和多肽药物的稳定类似物
US7329725B1 (en) 2003-10-29 2008-02-12 Nastech Pharmaceutical Company Inc. Phage displayed Trp cage ligands
AU2005203925A1 (en) 2004-01-08 2005-07-21 Theratechnologies Inc. Glucagon-Like Peptide-1 analogs with long duration of action
CA2555894A1 (en) 2004-02-11 2005-08-25 Amylin Pharmaceuticals, Inc. Pancreatic polypeptide family motifs and polypeptides comprising the same
US8076288B2 (en) 2004-02-11 2011-12-13 Amylin Pharmaceuticals, Inc. Hybrid polypeptides having glucose lowering activity
JP2008515856A (ja) 2004-10-07 2008-05-15 ノボ ノルディスク アクティーゼルスカブ 遅延性ｇｌｐ−１化合物
WO2006037811A2 (en) 2004-10-07 2006-04-13 Novo Nordisk A/S Protracted exendin-4 compounds
EP1838336A2 (de) * 2004-12-24 2007-10-03 Amylin Pharmaceuticals, Inc. Verwendung von glp-1 und seinen agonisten zur prävention von kardialer myozytenapoptose
WO2006083761A2 (en) 2005-02-03 2006-08-10 Alza Corporation Solvent/polymer solutions as suspension vehicles
US11246913B2 (en) 2005-02-03 2022-02-15 Intarcia Therapeutics, Inc. Suspension formulation comprising an insulinotropic peptide
CA2597649A1 (en) 2005-02-11 2006-08-17 Amylin Pharmaceuticals, Inc. Gip analog and hybrid polypeptides with selectable properties
US8263545B2 (en) 2005-02-11 2012-09-11 Amylin Pharmaceuticals, Inc. GIP analog and hybrid polypeptides with selectable properties
KR20080021636A (ko) * 2005-05-05 2008-03-07 카딜라 핼쓰캐어 리미티드 Ｇｌｐ-1 아고니스트인 신규 화합물
CN100429227C (zh) 2005-06-29 2008-10-29 常州制药厂有限公司 Exendin4多肽片段
EP1922336B1 (de) * 2005-08-11 2012-11-21 Amylin Pharmaceuticals, LLC Hybridpolypeptide mit auswählbaren eigenschaften
EA014647B1 (ru) * 2005-08-11 2010-12-30 Амилин Фармасьютикалз, Инк. Гибридные полипептиды с селектируемыми свойствами
US20090286722A1 (en) * 2005-09-08 2009-11-19 Utech Limited Analogs of Gastric Inhibitory Polypeptide as a Treatment for Age Related Decreased Pancreatic Beta Cell Function
WO2007028633A2 (en) * 2005-09-08 2007-03-15 Uutech Limited Treatment of diabetes related obesity
CN101262874A (zh) * 2005-09-08 2008-09-10 塔夫茨大学信托人 稳定化的glp-1类似物
EA015169B1 (ru) 2005-09-14 2011-06-30 Такеда Фармасьютикал Компани Лимитед Применение ингибиторов дипептидилпептидазы
CN102675221A (zh) 2005-09-16 2012-09-19 武田药品工业株式会社 用于制备嘧啶二酮衍生物的方法中的中间体
DE602005017628D1 (de) 2005-09-22 2009-12-24 Biocompatibles Uk Ltd Fusionspolypeptide vom glp-1 (glucagon-like peptide-1) mit erhöhten peptidaseresistenz
CN101534846B (zh) 2005-11-07 2014-11-05 印第安纳大学研究及科技有限公司 显示生理学溶解性和稳定性的胰高血糖素类似物
WO2007112347A1 (en) 2006-03-28 2007-10-04 Takeda Pharmaceutical Company Limited Dipeptidyl peptidase inhibitors
EP2004213A1 (de) * 2006-04-03 2008-12-24 Novo Nordisk A/S Glp-1-peptid-agonisten
CA2648936C (en) * 2006-04-20 2013-07-09 Amgen Inc. Glp-1 compounds
DE602006009631D1 (de) 2006-05-10 2009-11-19 Biocompatibles Uk Ltd GLP-1 Peptide enthaltende kugelförmige Mikrokapseln, deren Produktion und deren Verwendung
JP5143131B2 (ja) 2006-05-30 2013-02-13 インターシア セラピューティクス，インコーポレイティド 浸透圧送出システムの二片構成内部チャネル型の流れモジュレータ
PL2359808T3 (pl) 2006-08-09 2013-10-31 Intarcia Therapeutics Inc Osmotyczne systemy dostawcze i zespoły tłokowe
US8497240B2 (en) 2006-08-17 2013-07-30 Amylin Pharmaceuticals, Llc DPP-IV resistant GIP hybrid polypeptides with selectable properties
US8324383B2 (en) 2006-09-13 2012-12-04 Takeda Pharmaceutical Company Limited Methods of making polymorphs of benzoate salt of 2-[[6-[(3R)-3-amino-1-piperidinyl]-3,4-dihydro-3-methyl-2,4-dioxo-1(2H)-pyrimidinyl]methyl]-benzonitrile
TW200838536A (en) 2006-11-29 2008-10-01 Takeda Pharmaceutical Polymorphs of succinate salt of 2-[6-(3-amino-piperidin-1-yl)-3-methyl-2,4-dioxo-3,4-dihydro-2H-pyrimidin-1-ylmethy]-4-fluor-benzonitrile and methods of use therefor
US8669228B2 (en) 2007-01-05 2014-03-11 Indiana University Research And Technology Corporation Glucagon analogs exhibiting enhanced solubility in physiological pH buffers
RU2413528C2 (ru) 2007-01-18 2011-03-10 Открытое Акционерное Общество "Валента Фармацевтика" Лекарственный препарат для лечения сахарного диабета на основе экзенатида и даларгина, применение и способ лечения
AU2008216265B2 (en) 2007-02-15 2014-04-03 Indiana University Research And Technology Corporation Glucagon/GLP-1 receptor co-agonists
US8093236B2 (en) 2007-03-13 2012-01-10 Takeda Pharmaceuticals Company Limited Weekly administration of dipeptidyl peptidase inhibitors
EP1972349A1 (de) * 2007-03-21 2008-09-24 Biocompatibles UK Limited Mit Polymer(en) konjugierte GLP-1-Fusionspeptide, ihre Herstellung und Verwendung
EP1975176A1 (de) * 2007-03-27 2008-10-01 Biocompatibles UK Limited Neue GLP-1-Fusionspeptide, ihre Herstellung und Verwendung
MX2009011123A (es) 2007-04-23 2009-11-02 Intarcia Therapeutics Inc Formulaciones de suspensiones de peptidos insulinotropicos y sus usos.
ES2550363T3 (es) * 2007-09-05 2015-11-06 Novo Nordisk A/S Derivados truncados de GLP-1 y su uso terapéutico
EP2190460B1 (de) * 2007-09-05 2014-12-17 Novo Nordisk A/S Mit a-b-c-d derivatisierte peptide und ihre therapeutische verwendung
EP2679597A1 (de) 2007-09-05 2014-01-01 Novo Nordisk A/S Glucagonähnliche Peptid-1-Derivate und ihre pharmazeutische Verwendung
GB0717388D0 (en) 2007-09-07 2007-10-17 Uutech Ltd Use of GIP for the treatment of disorders associated with dysfunctional synaptic transmission
GB0717399D0 (en) 2007-09-07 2007-10-17 Uutech Ltd Use of GLP-1 analogues for the treatment of disorders associated with dysfunctional synaptic transmission
CA2707861A1 (en) 2007-10-30 2009-05-07 Indiana University Research And Technology Corporation Glucagon antagonists
JP5771005B2 (ja) 2007-10-30 2015-08-26 インディアナ ユニバーシティー リサーチ アンド テクノロジー コーポレーションＩｎｄｉａｎａ Ｕｎｉｖｅｒｓｉｔｙ Ｒｅｓｅａｒｃｈ Ａｎｄ Ｔｅｃｈｎｏｌｏｇｙ Ｃｏｒｐｏｒａｔｉｏｎ グルカゴンアンタゴニスト及びｇｌｐ−１アゴニスト活性を示す化合物
EP2240155B1 (de) 2008-02-13 2012-06-06 Intarcia Therapeutics, Inc Vorrichtungen, formulierungen und verfahren zur freisetzung mehrerer wirkstoffe
US20110245173A1 (en) * 2008-06-03 2011-10-06 Bachovchin William W Long-Acting GLP-1 Derivatives, and Methods of Treating Cardiac Dysfunction
CN102088989B (zh) 2008-06-17 2014-11-26 印第安纳大学研究及科技有限公司 在生理pH缓冲液中具有增强的溶解性和稳定性的胰高血糖素类似物
TWI474835B (zh) 2008-06-17 2015-03-01 Univ Indiana Res & Tech Corp 用於治療代謝病症及肥胖症之基於ｇｉｐ之混合激動劑
PE20100255A1 (es) 2008-06-17 2010-04-25 Univ Indiana Res & Tech Corp Co-agonistas del receptor de glucagon/glp-1
KR101939557B1 (ko) 2008-10-17 2019-01-17 사노피-아벤티스 도이칠란트 게엠베하 인슐린과 ｇｌｐ－1 효능제의 병용물
JP2012512903A (ja) 2008-12-19 2012-06-07 インディアナ ユニバーシティー リサーチ アンド テクノロジー コーポレーション アミド系グルカゴンスーパーファミリーペプチドプロドラッグ
WO2010076809A2 (en) * 2008-12-29 2010-07-08 Panacea Biotec Ltd Glp-1 analogs and uses thereof
US8642544B2 (en) 2009-04-01 2014-02-04 Amylin Pharmaceuticals, Llc N-terminus conformationally constrained GLP-1 receptor agonist compounds
WO2010118034A2 (en) * 2009-04-06 2010-10-14 Board Of Regents, The University Of Texas System Cyclic peptide analogues for non-invasive imaging of pancreatic beta-cells
AU2010260058B2 (en) 2009-06-16 2015-09-24 Indiana University Research And Technology Corporation GIP receptor-active glucagon compounds
US20120148586A1 (en) * 2009-08-27 2012-06-14 Joyce Ching Tsu Chou Glucagon-like protein-1 receptor (glp-1r) agonists for treating autoimmune disorders
NZ598686A (en) 2009-09-28 2014-05-30 Intarcia Therapeutics Inc Rapid establishment and/or termination of substantial steady-state drug delivery
RU2537239C2 (ru) 2009-11-13 2014-12-27 Санофи-Авентис Дойчланд Гмбх Фармацевтическая композиция, включающая агонист glp-1, инсулин и метионин
AU2010317994B2 (en) 2009-11-13 2014-03-06 Sanofi-Aventis Deutschland Gmbh Pharmaceutical composition comprising a GLP-1 agonist and methionine
US8703701B2 (en) 2009-12-18 2014-04-22 Indiana University Research And Technology Corporation Glucagon/GLP-1 receptor co-agonists
CA2788304A1 (en) 2010-01-27 2011-08-04 Indiana University Research And Technology Corporation Glucagon antagonist - gip agonist conjugates and compositions for the treatment of metabolic disorders and obesity
KR20130062931A (ko) 2010-05-13 2013-06-13 인디애나 유니버시티 리서치 앤드 테크놀로지 코퍼레이션 핵 호르몬 수용체 활성을 나타내는 글루카곤 슈퍼패밀리 펩티드
WO2011143208A1 (en) 2010-05-13 2011-11-17 Indiana University Research And Technology Corporation Glucagon superfamily peptides exhibiting g protein-coupled receptor activity
RU2580317C2 (ru) 2010-06-24 2016-04-10 Индиана Юниверсити Рисерч Энд Текнолоджи Корпорейшн Пептидные пролекарства, принадлежащие к суперсемейству амид-содержащих глюкагонов
CN103179978A (zh) 2010-08-30 2013-06-26 赛诺菲-安万特德国有限公司 Ave0010用于制造供治疗2型糖尿病用的药物的用途
US9023986B2 (en) 2010-10-25 2015-05-05 Hoffmann-La Roche Inc. Glucose-dependent insulinotropic peptide analogs
DK3326620T3 (da) 2010-12-16 2020-05-25 Novo Nordisk As Faste sammensætninger omfattende en glp-1-agonist og et salt af n-(8-(2- hydroxybenzoyl)amino)caprylsyre
EA201390941A1 (ru) 2010-12-22 2013-12-30 Индиана Юниверсити Рисерч Энд Текнолоджи Корпорейшн Аналоги глюкагона, проявляющие активность на рецепторе gip
US9050347B2 (en) 2011-01-25 2015-06-09 Viviabiotech, S.L. 1,2,4-oxadiazole derivatives as drugs modulating the GLP-1 peptide receptor
US20120208755A1 (en) 2011-02-16 2012-08-16 Intarcia Therapeutics, Inc. Compositions, Devices and Methods of Use Thereof for the Treatment of Cancers
MX355361B (es) 2011-04-12 2018-04-17 Novo Nordisk As Derivados de peptido 1 tipo glucagon (glp-1) doblemente acilados.
WO2012145523A2 (en) 2011-04-20 2012-10-26 The United States Of America, As Represented By The Secretary, Department Of Health & Human Services Aav mediated exendin-4 gene transfer to salivary glands to protect subjects from diabetes or obesity
US9821032B2 (en) 2011-05-13 2017-11-21 Sanofi-Aventis Deutschland Gmbh Pharmaceutical combination for improving glycemic control as add-on therapy to basal insulin
US20140221283A1 (en) 2011-06-22 2014-08-07 Indiana University Research And Technology Corporation Glucagon/glp-1 receptor co-agonists
US9309301B2 (en) 2011-06-22 2016-04-12 Indiana University Research And Technology Corporation Glucagon/GLP-1 receptor co-agonists
JP6367115B2 (ja) 2011-08-29 2018-08-01 サノフィ−アベンティス・ドイチュラント・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング ２型糖尿病患者の血糖コントロールに使用する組合せ医薬
AR087744A1 (es) 2011-09-01 2014-04-16 Sanofi Aventis Deutschland Composicion farmaceutica para uso en el tratamiento de una enfermedad neurodegenerativa
CA2847246A1 (en) 2011-11-17 2013-05-23 Indiana University Research And Technology Corporation Glucagon superfamily peptides exhibiting glucocorticoid receptor activity
US9388212B2 (en) 2013-02-21 2016-07-12 Chemical & Biopharmaceutical Laboratories Of Patras S.A. Solid phase peptide synthesis via side chain attachment
AU2013234496B2 (en) 2012-03-22 2017-07-27 Novo Nordisk A/S Compositions of GLP-1 peptides and preparation thereof
HUE042757T2 (hu) 2012-03-22 2019-07-29 Novo Nordisk As Szállító szert tartalmazó készítmények és elõállításuk
ES2871328T3 (es) 2012-06-20 2021-10-28 Novo Nordisk As Formulación de comprimido que comprende un péptido y un agente de suministro
ES2602486T3 (es) 2012-06-21 2017-02-21 Indiana University Research And Technology Corporation Análogos de glucagón que muestran actividad de receptor de GIP
UA116217C2 (uk) 2012-10-09 2018-02-26 Санофі Пептидна сполука як подвійний агоніст рецепторів glp1-1 та глюкагону
WO2014088631A1 (en) * 2012-12-06 2014-06-12 Stealth Peptides International, Inc. Peptide therapeutics and methods for using same
JP2016503046A (ja) * 2012-12-19 2016-02-01 ノヴォ ノルディスク アー／エス コレステロール流出活性を有する新規ｇｌｐ−１受容体アゴニスト
AU2013366691A1 (en) 2012-12-21 2015-07-09 Sanofi Exendin-4 derivatives
JP6382488B2 (ja) * 2013-02-21 2018-08-29 ケミカル アンド バイオファーマシューティカル ラボラトリーズ オブ パトラ エス．エー． 側鎖結合を介する固相ペプチド合成
WO2015070050A1 (en) 2013-11-08 2015-05-14 Baylor Research Institute Nuclear loclization of glp-1 stimulates myocardial regeneration and reverses heart failure
WO2015081891A1 (en) 2013-12-06 2015-06-11 Baikang (Suzhou) Co., Ltd Bioreversable promoieties for nitrogen-containing and hydroxyl-containing drugs
TW201609797A (zh) 2013-12-13 2016-03-16 賽諾菲公司 雙重ｇｌｐ－１／升糖素受體促效劑
TW201609796A (zh) 2013-12-13 2016-03-16 賽諾菲公司 非醯化之艾塞那肽－４（ｅｘｅｎｄｉｎ－４）胜肽類似物
EP3080150B1 (de) 2013-12-13 2018-08-01 Sanofi Exendin-4-peptidanaloga als duale glp-1/gip-rezeptoragonisten
TW201609799A (zh) 2013-12-13 2016-03-16 賽諾菲公司 雙重ｇｌｐ－１／ｇｉｐ受體促效劑
TW201625668A (zh) 2014-04-07 2016-07-16 賽諾菲公司 作為胜肽性雙重ｇｌｐ－１／昇糖素受體激動劑之艾塞那肽－４衍生物
TW201625670A (zh) 2014-04-07 2016-07-16 賽諾菲公司 衍生自ｅｘｅｎｄｉｎ－４之雙重ｇｌｐ－１／升糖素受體促效劑
TW201625669A (zh) 2014-04-07 2016-07-16 賽諾菲公司 衍生自艾塞那肽－４（Ｅｘｅｎｄｉｎ－４）之肽類雙重ＧＬＰ－１／升糖素受體促效劑
US9932381B2 (en) 2014-06-18 2018-04-03 Sanofi Exendin-4 derivatives as selective glucagon receptor agonists
GB201415598D0 (en) * 2014-09-03 2014-10-15 Univ Birmingham Elavated Itercranial Pressure Treatment
US9889085B1 (en) 2014-09-30 2018-02-13 Intarcia Therapeutics, Inc. Therapeutic methods for the treatment of diabetes and related conditions for patients with high baseline HbA1c
NZ733670A (en) 2014-12-12 2021-12-24 Sanofi Aventis Deutschland Insulin glargine/lixisenatide fixed ratio formulation
US11135271B2 (en) 2014-12-30 2021-10-05 Hanmi Pharm. Co., Ltd. Glucagon derivatives with improved stability
TWI748945B (zh) 2015-03-13 2021-12-11 德商賽諾菲阿凡提斯德意志有限公司 第２型糖尿病病患治療
TW201705975A (zh) 2015-03-18 2017-02-16 賽諾菲阿凡提斯德意志有限公司 第２型糖尿病病患之治療
US10993993B2 (en) 2015-05-28 2021-05-04 Immunoforge Co., Ltd. Pharmaceutical composition for treating muscle atrophy or sarcopenia including glucagon-like peptide (GLP-1) or GLP-1 receptor agonist
KR101661332B1 (ko) * 2015-05-28 2016-09-29 (의료)길의료재단 글루카곤 유사 펩타이드-1 수용체 항진제를 포함하는 근감소증 치료용 약학 조성물
AU2016270984B2 (en) 2015-06-03 2021-02-25 Intarcia Therapeutics, Inc. Implant placement and removal systems
AR105319A1 (es) 2015-06-05 2017-09-27 Sanofi Sa Profármacos que comprenden un conjugado agonista dual de glp-1 / glucagón conector ácido hialurónico
MA49545B1 (fr) 2015-06-30 2022-03-31 Hanmi Pharm Ind Co Ltd Dérivé de glucagon et composition comprenant un conjugué à action prolongée de celui-ci
TW201706291A (zh) 2015-07-10 2017-02-16 賽諾菲公司 作為選擇性肽雙重ｇｌｐ－１／升糖素受體促效劑之新毒蜥外泌肽（ｅｘｅｎｄｉｎ－４）衍生物
AU2016379403B2 (en) * 2015-12-23 2020-03-12 The Johns Hopkins University Long-acting GLP-1r agonist as a therapy of neurological and neurodegenerative conditions
CN116063454A (zh) * 2015-12-31 2023-05-05 韩美药品株式会社 胰高血糖素/glp-1/gip受体三重激动剂
CN109310743A (zh) 2016-05-16 2019-02-05 因塔西亚制药公司 胰高血糖素受体选择性多肽及其使用方法
USD840030S1 (en) 2016-06-02 2019-02-05 Intarcia Therapeutics, Inc. Implant placement guide
USD860451S1 (en) 2016-06-02 2019-09-17 Intarcia Therapeutics, Inc. Implant removal tool
UA126662C2 (uk) 2016-06-29 2023-01-11 Ханмі Фарм. Ко., Лтд. Похідна глюкагону, її кон'югат, композиція, яка її містить, та її терапевтичне застосування
CA3040906A1 (en) 2016-10-20 2018-04-26 Peptron, Inc. Methods of delivering a neuroprotective polypeptide to the central nervous system
EP3565580B1 (de) 2017-01-03 2024-03-06 i2o Therapeutics, Inc. Kontinuierlicher verabreichung von exenatid und co-verabreichung von acetaminophen, ethinylestradiol oder levonorgestrel
IL275778B2 (en) 2018-02-02 2023-12-01 Novo Nordisk As Solid compounds that make up glp-1 agonist n-8-2-hydroxybenzoyl salt
CN110452952B (zh) * 2018-05-08 2024-01-16 宜昌东阳光长江药业股份有限公司 一种glp-1类似物生物活性的检测方法
KR101921085B1 (ko) 2018-05-21 2018-11-22 이뮤노포지 주식회사 글루카곤 유사 펩타이드-1(glp-1), glp-1 유래 펩타이드, 또는 glp-1 분해 억제제를 포함하는 근감소증 또는 근위축증 치료용 약학 조성물
KR102119188B1 (ko) * 2018-11-13 2020-06-08 이뮤노포지 주식회사 글루카곤 유사 펩타이드-1(glp-1), glp-1 유래 펩타이드, 또는 glp-1 분해 억제제를 포함하는 근감소증 또는 근위축증 치료용 약학 조성물
WO2020175570A1 (ja) * 2019-02-28 2020-09-03 新田ゼラチン株式会社 脳機能調整剤、およびこれを含む飲食品
WO2020214012A1 (ko) * 2019-04-19 2020-10-22 한미약품 주식회사 글루카곤, glp-1 및 gip 수용체 모두에 활성을 갖는 삼중 활성체 또는 이의 결합체를 포함하는 고지혈증 예방 또는 치료용 약학적 조성물 및 예방 또는 치료 방법
WO2020214013A1 (ko) * 2019-04-19 2020-10-22 한미약품 주식회사 글루카곤, glp-1 및 gip 수용체 모두에 활성을 갖는 삼중 활성체 또는 이의 결합체의 고지혈증에 대한 치료적 용도
AU2020331939A1 (en) 2019-08-16 2022-03-24 Applied Molecular Transport Inc. Compositions, formulations, and interleukin production and purification
CA3164565A1 (en) * 2020-01-13 2021-07-22 Seon Myeong Lee Therapeutic use of long-acting conjugate of triple agonist having activities to all of glucagon/glp-1/gip receptors for lung disease

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3710795A (en) 1970-09-29 1973-01-16 Alza Corp Drug-delivery device with stretched, rate-controlling membrane
US5424286A (en) * 1993-05-24 1995-06-13 Eng; John Exendin-3 and exendin-4 polypeptides, and pharmaceutical compositions comprising same
CA2137206A1 (en) * 1993-12-09 1995-06-10 John A. Galloway Glucagon-like insulinotropic peptides, compositions and methods
GB9409496D0 (en) 1994-05-12 1994-06-29 London Health Ass Method for improving glycaemic control in diabetes
US5574008A (en) * 1994-08-30 1996-11-12 Eli Lilly And Company Biologically active fragments of glucagon-like insulinotropic peptide
ATE316100T1 (de) * 1996-06-05 2006-02-15 Roche Diagnostics Gmbh Exendin-analoga, verfahren zu deren herstellung und diese enthaltende arzneimittel
ES2425559T5 (es) * 1997-01-07 2018-02-02 Amylin Pharmaceuticals, Llc Composiciones farmacéuticas que comprenden las exendinas y los agonistas de las mismas
US6268479B1 (en) * 1997-03-12 2001-07-31 The Trustees Of Columbia University In The City Of New York Intracellular amyloid-beta peptide binding (ERAB) polypeptide
WO1999038501A2 (en) * 1998-02-02 1999-08-05 Trustees Of Tufts College Method of regulating glucose metabolism, and reagents related thereto
ATE366115T1 (de) 1998-02-13 2007-07-15 Amylin Pharmaceuticals Inc Inotropische und diuretische effekte von exendin und glp-1
EP1056774A1 (de) 1998-02-27 2000-12-06 Novo Nordisk A/S N-terminal verkürzte glp-1 derivate
JP4394279B2 (ja) 1998-03-09 2010-01-06 ジーランド ファーマ アクティーゼルスカブ 酵素加水分解に対する傾向が減少した薬理学的に活性なペプチド複合体
DE19828113A1 (de) 1998-06-24 2000-01-05 Probiodrug Ges Fuer Arzneim Prodrugs von Inhibitoren der Dipeptidyl Peptidase IV
CA2339326A1 (en) 1998-08-10 2000-02-24 Josephine Egan Differentiation of non-insulin producing cells into insulin producing cells by glp-1 or exendin-4 and uses thereof
MY155270A (en) * 1998-09-24 2015-09-30 Lilly Co Eli Use of glp-1 or analogs in treatment of stroke
US6429197B1 (en) * 1998-10-08 2002-08-06 Bionebraska, Inc. Metabolic intervention with GLP-1 or its biologically active analogues to improve the function of the ischemic and reperfused brain
KR100458748B1 (ko) * 1998-12-07 2004-12-03 더 어드미니스트레이터즈 오브 더 튜래인 어듀케이셔널 훤드 Ｇｌｐ-1 유사체
EP2322545A1 (de) * 1998-12-07 2011-05-18 Ipsen Pharma GLP-1 Analoge
JP3136356B2 (ja) 1998-12-15 2001-02-19 農林水産省家畜衛生試験場長 改変型シグナルペプチドをコードするｄｎａ
CA2356706C (en) * 1999-01-14 2014-09-30 Amylin Pharmaceuticals, Inc. Novel exendin agonist formulations and methods of administration thereof
DK1189629T3 (da) 1999-02-10 2011-01-03 Curis Inc Peptid YY (PYY) til behandling af glucosestofskiftesygdomme
SI1180121T1 (en) * 1999-05-17 2004-04-30 Conjuchem, Inc. Long lasting insulinotropic peptides
US6506724B1 (en) * 1999-06-01 2003-01-14 Amylin Pharmaceuticals, Inc. Use of exendins and agonists thereof for the treatment of gestational diabetes mellitus
EP1076066A1 (de) * 1999-07-12 2001-02-14 Zealand Pharmaceuticals A/S Peptide zur Senkung des Blutglukosespiegels
WO2001034200A1 (fr) * 1999-11-10 2001-05-17 Takeda Chemical Industries, Ltd Inhibiteurs de prise de poids
US6278018B1 (en) 1999-12-14 2001-08-21 Surmodics, Inc. Surface coating agents
US20030036504A1 (en) 2000-01-10 2003-02-20 Amylin Pharmaceuticals, Inc. Use of exendins and agonists thereof for modulation of triglyceride levels and treatment of dyslipidemia
AU2001232337A1 (en) * 2000-02-18 2001-08-27 Kanagawa Academy Of Science And Technology Pharmaceutical composition, reagent and method for intracerebral delivery of pharmaceutically active ingredient or labeling substance
EP1136071A3 (de) * 2000-03-22 2003-03-26 Pfizer Products Inc. Verwendung von Glykogen-Phosphorylase-Hemmern
EP1313767A2 (de) * 2000-08-24 2003-05-28 Thomas Jefferson University Peptid zur besserung der gehirnwirkung
CA2434237C (en) * 2000-12-07 2012-05-15 Eli Lilly And Company Glp-1 fusion proteins
EP2022505B1 (de) 2001-07-31 2011-12-14 The Government of the United States of America, as represented by the Secretary of the Department of Health and Human Services GLP-1, Exendin-4, Peptid-Analoga und Verwendungen davon
ES2343061T3 (es) * 2002-05-24 2010-07-22 Medtronic, Inc. Metodos y constructos de dna para produccion de polipeptidos con rendimiento alto.
US6969702B2 (en) * 2002-11-20 2005-11-29 Neuronova Ab Compounds and methods for increasing neurogenesis
DOP2006000008A (es) * 2005-01-10 2006-08-31 Arena Pharm Inc Terapia combinada para el tratamiento de la diabetes y afecciones relacionadas y para el tratamiento de afecciones que mejoran mediante un incremento de la concentración sanguínea de glp-1
BRPI0616456A2 (pt) 2005-09-28 2011-06-21 Ventria Bioscience formulação para prevenir ou tratar distúrbios entérico, diarréia ou doença intestinal inflamatória ou para promover o crescimento da flora intestinal benéfica, solução de re-hidratação oral e formulação de re-hidratação oral sob a forma de um pó ou de um concentrado lìquido
JP2013007734A (ja) 2011-01-17 2013-01-10 Nippon Dempa Kogyo Co Ltd 外力検出装置及び外力検出センサー

Also Published As

Publication number Publication date
US8853160B2 (en) 2014-10-07
EP2275117B1 (de) 2016-10-26
ATE408414T1 (de) 2008-10-15
EP1411968B1 (de) 2008-09-17
US8278272B2 (en) 2012-10-02
EP2022505A2 (de) 2009-02-11
ATE536881T1 (de) 2011-12-15
JP5695097B2 (ja) 2015-04-01
EP2022505A3 (de) 2009-05-27
EP1411968A4 (de) 2005-06-15
JP2013139447A (ja) 2013-07-18
CA2455963A1 (en) 2003-02-13
WO2003011892A2 (en) 2003-02-13
EP1411968A2 (de) 2004-04-28
JP2005501058A (ja) 2005-01-13
US20090253625A1 (en) 2009-10-08
EP2275117A1 (de) 2011-01-19
US20150072930A1 (en) 2015-03-12
US7576050B2 (en) 2009-08-18
US10941187B2 (en) 2021-03-09
AU2008202893B2 (en) 2012-01-12
JP5631578B2 (ja) 2014-11-26
AU2008202893A1 (en) 2008-07-24
US20120329715A1 (en) 2012-12-27
JP2010090129A (ja) 2010-04-22
AU2002317599B2 (en) 2008-04-03
US20040242853A1 (en) 2004-12-02
WO2003011892A3 (en) 2004-02-26
EP2022505B1 (de) 2011-12-14
CA2455963C (en) 2017-07-04

Similar Documents

Publication Publication Date Title
DE60228972D1 (de) Glp 1 exendin 4 peptidanaloga und deren verwendungen
DK0699686T3 (da) Biologisk aktive fragmenter af glukagon-lignende insulinotropisk peptid
PE20011363A1 (es) Analogos del peptido-1 semejante a glucagon
EA200100289A1 (ru) Способ введения инсулинотропных пептидов
EP0464022A4 (en) Insulinotropic hormone
WO2002048192A3 (en) Amidated glucagon-like peptide-1
WO2003033671A3 (en) Human glucagon-like-peptide-1 mimics and their use in the treatment of diabetes and related conditions
DE602004029086D1 (de) Intranasale verabreichung von glucose-regulierenden peptiden
NO940436L (no) Forlenget avgivelse av peptider
WO1999043705A8 (en) N-terminally truncated glp-1 derivatives
DE60134251D1 (de) Verwendung von glp-2-peptiden
FI954941A (fi) Glukagonintapaisia insuliinitrooppisia peptidianalogeja, koostumuksia ja käyttömenetelmiä
WO2007028394A3 (en) Use of a glp-1 molecule for treatment of biliary dyskinesia and/or biliary pain/discomfort
DE602006020123D1 (de) Glucagon-like-peptide-2- (glp-2-) analoga
DE69327309D1 (de) Verwendung eines peptids
ATE394423T1 (de) Analoge des glucagon ähnlichen peptides-1 (glp-1)
DK0512042T3 (da) GLP-1-analoger anvendelige ved diabetesbehandling
DK0762890T3 (da) Behandling af diabetes
DK0733644T3 (da) Glucagonlignende, insulinotrope komplekser, sammensætninger og fremgangsmåder
DK1171465T3 (da) Analoger til gastroinhibitorisk peptid og deres anvendelse til behandling af diabetes
PT1751184E (pt) Proteínas de fusão de fgf-21
IL90975A0 (en) Non-glycosylated,recombining human il 2 in reduced form,the process for obtaining it and its use as a medicament
ECSP993116A (es) Procedimiento para administrar peptidos insulinotropicos

Legal Events

Date Code Title Description
8364 No opposition during term of opposition